EXACT Therapeutics AS (DE:56F) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EXACT Therapeutics has received FDA clearance for its Phase 2 ENACT trial, which will test the Acoustic Cluster Therapy (ACT®) in combination with modified FOLFIRINOX for pancreatic cancer treatment. The company plans to share safety review results by mid-2025, marking a significant step in its strategic goals to enhance targeted drug delivery in oncology.
For further insights into DE:56F stock, check out TipRanks’ Stock Analysis page.